Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 4 , Pages 377-388 , July 2010

p53 immunohistochemistry in bladder cancer—a new approach to an old question

  • Peter J. Goebell, M.D.

      Affiliations

    • Department of Urology, Friedrich-Alexander University Erlangen, Erlangen, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 (0) 9131-822-3122; fax: +49 (0) 9131-822-3179
    • ,
  • Susan G. Groshen, Ph.D.

      Affiliations

    • Department of Preventive Medicine and Biostatistics, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Keck School of Medicine, Los Angeles, CA 90089, USA
    • ,
  • Bernd J. Schmitz-Dräger, M.D., Ph.D.

      Affiliations

    • Department of Urology, Euromed Clinic, Fürth, Germany
    • ,
  • International Study-Initiative on Bladder Cancer (ISBC)

      Affiliations

    • The members of the ISBC and participants of this trial are: Bernd J. Schmitz-Dräger, Fürth, Peter J. Goebell, Erlangen, Guido Sauter, Hamburg, Germany, Thomas C. Gasser, Basel, Switzerland, Yves Fradet, Quebec, Canada, Helene LaRue, Quebec, Canada, Pertti K. Lipponen, Kuopio, Finland, Tapani JO Liukkonen, Mikkeli, Finland, Pertti Rajala, Mikkeli, Finland, M′Liss Ann Hudson, Washington, USA, Peter A. Humphrey, Washington, USA, Giovanni Casetta, Torino, Italy, Alessandro Tizziani, Torino, Italy, Stefan Wellek, Mannheim, Germany, Michael Stöckle, Homburg, Germany, Staffan Jahnson, Örebrö, Sweden, Björn Risberg, Oslo, Norway, Pier Francesco Bassi, Rome, Italy, Anna Rosa Del Mistro, Padova, Italy, T.R. Leyshon Griffiths, Leicester, UK, David E. Neal, Cambridge, UK, Mutsuo Furihata, Kochi, Nankoku, Japan, †Dominique Chopin, Creteil, France, Zivko Popov, Creteil, France, Alan Pollack, Houston, USA, Gunar Zagars, Houston, USA, Paolo Dalla Palma, Trento, Italy, Lucio Luciani, Trento, Italy, Lydia Nakopoulou, Athens, Greece, Robert A. Gardiner, Herson, Australia, Mark A. Underwood, Glasgow, UK, Yoshiyuki Kakehi, Kagawa, Japan, Toyoaki Uchida, Kitasato, Japan, Jack Schalken, Nijmegen, The Netherlands, Alexandre R. Zlotta, Toronto, Canada, H. Barton Grossman, Houston, USA, George N. Thalman, Bern, Switzerland, David J. Thomas, Leeds, UK.

References 

  1. Brown CJ, Lain S, Verma CS, et al. Awakening guardian angels: Drugging the p53 pathway. Nat Rev Cancer. 2009;9:862–873
  2. Malats N, Kogevinas M, Bustos A, et al. Bladder cancer and p53: An example of what should not be done in biomarker research. Int J Biol Markers. 2000;15:S30
  3. Schmitz-Dräger BJ, Goebell PJ, Ebert T, et al. p53 immunohistochemistry as a prognostic marker in bladder cancer: A new toy for urologic scientists?. Eur Urol. 2000;38:691–700
  4. Zlotta AR, Schulman CC. Biological markers in non-muscle-invasive bladder tumors and their prognostic significance. Urol Clin North Am. 2000;27:179–189
  5. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene. 1999;18:477–485
  6. Weisz L, Oren M, Rotter V. Transcription regulation by mutant p53. Oncogene. 2007;26:2202–2211
  7. Strano S, Dell'Orso S, Di Agostino S, et al. Mutant p53: An oncogenic transcription factor. Oncogene. 2007;26:2212–2219
  8. Soussi T. p53 alterations in human cancer: More questions than answers. Oncogene. 2007;26:2145–2156
  9. McShane LM, Aamodt R, Cordon-Cardo C, et al. Reproducibility of p53 immunohistochemistry in bladder tumors (National Cancer Institute, Bladder Tumor Marker Network). Clin Cancer Res. 2000;6:1854–1864
  10. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer. 1994;69:979–985
  11. Hayes DF. Determination of clinical utility of tumor markers: A tumor marker utility grading system. Recent Results Cancer Res. 1998;152:71–85
  12. Goebell PJ, Groshen SL, Schmitz-Dräger BJ. Guidelines for development of diagnostic markers in bladder cancer. World J Urol. 2008;26:5–11
  13. Mallett S, Timmer A, Sauerbrei W, et al. Reporting of prognostic studies of tumor markers: A review of published articles in relation to REMARK guidelines. Br J Cancer. 2010;102:173–180
  14. Shariat SF, Lotan Y, Vickers A, et al. Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol. 2010;28:389–400
  15. Schmitz-Dräger BJ, Goebell PJ, Heydthausen M. The International Study Initiative on Bladder Cancer (ISBC) (p53 Immunohistochemistry in bladder cancer: Combined analysis—a way to go?). Urol Oncol. 2000;5:204–215
  16. Shi SR, Cote RJ, Taylor CR. Antigen retrieval immunohistochemistry: Past, present, and future. J Histochem Cytochem. 1997;45:327–343
  17. Goebell PJ, Schmitz-Dräger BJ, Heydthausen M, et al. A critical look at antigen retrieval and choice of antibodies for p53 immunohistochemistry—technical aspects in the ISBC combined analysis. J Urol. 2002;167:453
  18. Keegan PE, Matthews JN, Lunec J, et al. Statistical problems with ‘optimal’ thresholds in studies of new prognostic factors in urology. BJU Int. 2000;85:392–397
  19. Furihata M, Inoue K, Ohtsuki Y, et al. High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder. Cancer Res. 1993;53:4823–4827
  20. Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer. 1993;53:365–370
  21. Thomas DJ, Robinson MC, Charlton R, et al. p53 Expression, ploidy, and progression in pT1 transitional cell carcinoma of the bladder. Br J Urol. 1994;73:533–537
  22. Gardiner RA, Walsh MD, Allen V, et al. Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumor progression. Br J Urol. 1994;73:526–532
  23. Hudson MA, Nadler RB, Swanson PE, et al. p53 Protein accumulation in superficial bladder cancer: A predictor of tumor progression which is not affected by intravesical BCG therapy. J Urol. 1995;153:531
  24. Jahnson S, Risberg B, Karlsson MG, et al. p53 and Rb immunostaining in locally advanced bladder cancer: Relation to prognostic variables and predictive value for the local response to radical radiotheraypy. Eur Urol. 1995;28:135–142
  25. Nakopoulou L, Constantinides C, Papandropoulos J, et al. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: Comparison with DNA ploidy. Urology. 1995;46:334–340
  26. Nakopoulou L, Vourlakou C, Zervas A, et al. The prevalence of bcl-2, p53 and Ki-67 immunoreactivity in transitional cell carcinomas and their clinicopathologic correlates. Hum Pathol. 1998;29:146–154
  27. Tetu B, Fradet Y, Allard P, et al. Prevalence and clinical significance of Her-2/neu, p53 and Rb expression in primary superficial bladder cancer. J Urol. 1996;155:1784–1788
  28. Underwood MA, Reeves J, Smith G, et al. Overexpression of p53 protein and its significance for recurrent progressive bladder tumors. Br J Urol. 1996;77:659–666
  29. Wu CS, Pollack A, Czerniak B, et al. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology. 1996;47:305–310
  30. Burkhard FC, Markwalder R, Thalmann GN, et al. Immunohistochemical determination of p53 overexpression: An easy and readily available method to identify progression in superficial bladder cancer?. Urol Res. 1997;25(Suppl.):31–35
  31. Casetta G, Gontero P, Russo R, et al. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder. Eur Urol. 1997;32:229–236
  32. Popov Z, Hoznek A, Colombel M, et al. Evaluations de la surexpression de la proteine p53 dans le cancer de la vessie: Valeur prognostique. Chirurgie. 1996;121:461–469
  33. Popov Z, Hoznek A, Colombel M, et al. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer. 1997;80:1472–1481
  34. Schmitz-Dräger BJ, Kushima M, Goebell P. p53 and mdm2 in the development and progression of bladder cancer. Eur Urol. 1997;32:487–493
  35. Abdel-Fattah R, Challen C, Griffiths TR, et al. Alterations of Tp53 in microdissected transitional cell carcinoma of the human urinary bladder: High frequency of Tp53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer. 1998;77:2230–2238
  36. Grossman HB, Liebert M, Antelo M, et al. p53 and Rb expression predict progression in T1 bladder cancer. Clin Cancer Res. 1998;4:829–834
  37. Kakehi Y, Ozdemir E, Habuchi T, et al. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas. Jpn J Cancer. 1998;89:214–220
  38. Zlotta A, Noel JC, Fayt I, et al. Correlation and prognostic significance of p53, p21, and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J Urol. 1999;161:792–798
  39. Moch H, Sauter G, Mihatsch MJ, et al. p53 but not erB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Hum Pathol. 1994;25:1346–1351
  40. Moch H, Sauter G, Moore D, et al. p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer. Virchows Arch A Pathol Anat Histopathol. 1993;423:329–334
  41. Qureshi KN, Griffith TR, Robinson MC, et al. Tp53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer. Clin Cancer Res. 1999;5:3500–3507
  42. Vet JA, Bringuier PP, Schaafsma HE, et al. Comparison of p53 protein overexpression with p53 mutation in bladder cancer: Clinical and biologic aspects. Lab Invest. 1995;73:837–843
  43. Barbareschi M, Girlando S, Fellin G, et al. Expression of mdm-2 and p53 protein in transitional cell carcinoma. Urol Res. 1995;22:349–352
  44. Leissner J, Gerber M, Fischer U, et al. Predictive value of p53 accumulation in patients with locally advanced bladder cancer. J Urol. 1996;155:615A
  45. Liukkonen T, Rajala P, Raitanen M, et al. Finbladder Group Prognostic value of MIB-1 Score, p53, EGFr, mitotic index, and papillary status in primary superficial (stage pTa/T1) bladder cancer: A prospective comparative study. Eur Urol. 1999;36:393–400
  46. Bassi P, Spinadin R, Carando R, et al. Dissecting stage T1 bladder cancers by p53. Eur Urol. 1998;34:297
  47. Hermanek P, Sobin LH. TNM Classification of Malignant Tumors. 4th ed.. Berlin, Heidelberg, New York: Springer; 1992;
  48. Mostofi FK. Histological Typing of Urinary Bladder Tumors. Geneva: Offset Publication 10, WHO; 1973;
  49. Spruck CH, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 1994;54:784–788
  50. Wu XR. Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer. 2005;5:713–725
  51. Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis. 2006;27:361–373
  52. Knowles MA. Bladder cancer subtypes defined by genomic alterations. Scand J Urol Nephrol. 2008;42:116–1304
  53. Kulkarni GS, Hakenberg OW, Gschwend JE, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol. 2010;57:60–70
  54. Fritsche HM, Burger M, Svatek RS, et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: Results from an international cohort. Eur Urol. 2010;57:300–309
  55. Soloway MS, Lee CT, Steinberg GD, et al. Difficult decisions in urologic oncology: Management of high-grade T1 transitional cell carcinoma of the bladder. Urol Oncol. 2007;25:338–340
  56. Witjes JA. Management of the first recurrence of T1G3 bladder cancer: Does intravesical chemotherapy deserve a chance?. Urol Oncol. 2009;27:322–324
  57. Kulkarni GS, Alibhai SM, Finelli A, et al. Cost-effectiveness analysis of immediate radical cystectomy versus intravesical bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer. 2009;115:5450–5459
  58. Herr HW. High-risk, high-grade (T1G3) bladder cancer: Models vs. reality. Cancer. 2009;115:5366–5367
  59. Queipo-Zaragoza JA, Ruiz-Cerda JL, Vera-Donoso CD, et al. Prognostic value of p53, Ki-67, microstaging, and microvessel density in pT1G3 bladder tumors: Creation of risk groups for progression. Scand J Urol Nephrol. 2007;41:283–289
  60. Serretta V, Morgia G, Altieri V, et al. Members of Gruppo Studi Tumori Urologici (GSTU) Foundation (2010). A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer. BJU Int.
  61. McShane LM, Altman DG, Sauerbrei W. Identification of clinically useful cancer prognostic factors: What are we missing?. J Natl Cancer Inst. 2005;97:1023–1025
  62. Sauerbrei W. Prognostic factors (Confusion caused by bad quality design, analysis, and reporting of many studies). Adv Otorhinolaryngol. 2005;62:184–200

☆ This trial was performed under the auspices of the International Bladder Cancer Network (IBCN).

PII: S1078-1439(10)00108-0

doi: 10.1016/j.urolonc.2010.03.021

Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 4 , Pages 377-388 , July 2010

Article Tools

* Image Usage & Resolution